(Q42914097)

English

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

scientific article published on October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

11 November 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

André J Scheen

1

1 reference

Europe PubMed Central

11 November 2017

Guillaume Charpentier

2

1 reference

Europe PubMed Central

11 November 2017

Carl Johan Ostgren

3

1 reference

Europe PubMed Central

11 November 2017

Asa Hellqvist

4

1 reference

Europe PubMed Central

11 November 2017

Ingrid Gause-Nilsson

5

1 reference

Europe PubMed Central

11 November 2017

publication date

1 October 2010

1 reference

Europe PubMed Central

11 November 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

11 November 2017

26

1 reference

Europe PubMed Central

11 November 2017

7

1 reference

Europe PubMed Central

11 November 2017

540-549

1 reference

Europe PubMed Central

11 November 2017

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

21 January 2018

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Earlier triple therapy with pioglitazone in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Use and abuse of HOMA modeling

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of incretin therapy to metformin in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Current management strategies for coexisting diabetes mellitus and obesity

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1114

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.1114

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42914097&oldid=1973527995"